To explore clinical efficacy of Jinlida Granules combined with Tongxinluo Capsules in the treatment for patients with stage IV diabetic nephropathy(DN).Methods:From March 2017 to March 2018，82 cases of stage IV DN admitted in Danzhou People's Hospital were selected as study objects.According to random number table method，they were divided into control group(n=41)and observation group(n=41).They were given irbesartan and Jinlida Granules+ Tongxinluo Capsules respectively.Improvement of indexes in renal function and hemorheology was observed.Results:After the treatment，whole blood high and low shear viscosities and plasma viscosity，fibrinogen and hematocrit in the observation group were significantly lower than those in the control group(t=19.234，15.070，2.977，5.270，17.181，P<0.05); Scr，BUN，Ccr，ET-1 and 24-UP were also significantly lower than those in the control group(t=14.008，3.514，10.308，2.640，20.044，P<0.05); after the treatment，levels of CRP and Cys-C in the observation group were significantly lower than those in the control group(t=34.151，12.212，P<0.05); the incidences of adverse reactions in the 2 groups were 7.32% and 4.88% respectively，and there was no significant difference(χ2=0.213，P>0.05).Conclusion:Applying Tongxinluo Capsules combined with Jinlida Granules in patients with stage IV DN can better improve renal function and urine protein of them，and reduce the level of inflammatory factors.It is helpful to effectively improve the overall efficacy in patients.